ACE-031

What is ACE-031?#

ACE-031 is a recombinant fusion protein that consists of the extracellular domain of human activin receptor type IIB (ActRIIB) fused to the Fc portion of human immunoglobulin G1 (IgG1). It was developed by Acceleron Pharma as a therapeutic agent for conditions characterized by muscle wasting, with the primary clinical target being Duchenne muscular dystrophy (DMD). The compound functions as a soluble decoy receptor that intercepts and neutralizes myostatin and other members of the TGF-beta superfamily before they can bind to their endogenous cell-surface receptors, effectively removing the molecular brake on muscle growth.

The development of ACE-031 was grounded in one of the most compelling biological discoveries of the late 20th century: the identification of myostatin (GDF-8) as a negative regulator of skeletal muscle mass. Animals and rare humans with natural myostatin loss-of-function mutations exhibit dramatic muscular hypertrophy, demonstrating that inhibiting the myostatin pathway could be a powerful strategy for treating muscle wasting diseases.

The Myostatin Pathway#

Myostatin Biology#

Myostatin, formally known as growth differentiation factor 8 (GDF-8), is a member of the TGF-beta superfamily of secreted growth factors. It is produced primarily by skeletal muscle cells and acts in an autocrine and paracrine fashion to inhibit muscle cell proliferation and differentiation. Under normal conditions, myostatin serves as a natural limiter of muscle mass, preventing excessive muscle growth.

Myostatin signals through binding to the activin receptor type IIB (ActRIIB) on the surface of muscle cells. This binding activates an intracellular signaling cascade through SMAD2 and SMAD3 transcription factors, which ultimately suppresses the expression of genes involved in muscle protein synthesis and promotes genes involved in muscle protein degradation. The result is a tonic inhibitory signal that constrains muscle growth.

The Decoy Receptor Strategy#

ACE-031 exploits this signaling pathway by acting as a molecular trap. The soluble ActRIIB extracellular domain in ACE-031 retains the ability to bind myostatin and other TGF-beta ligands with high affinity, but because it is not attached to a cell surface, it cannot transduce intracellular signals. Instead, it sequesters these ligands in the circulation, preventing them from reaching and activating their endogenous receptors on muscle cells. This effectively removes the myostatin inhibitory signal, allowing muscle growth pathways to proceed unopposed.

Ligand Promiscuity#

A critical aspect of ACE-031's pharmacology is that the ActRIIB receptor is not specific to myostatin alone. It also binds other TGF-beta superfamily ligands including activin A, activin B, GDF-11, and bone morphogenetic proteins (BMPs). This ligand promiscuity means that ACE-031 inhibits multiple signaling pathways simultaneously, which has implications for both its therapeutic potency (it may produce greater muscle effects than myostatin-specific inhibitors) and its safety profile (inhibition of non-myostatin pathways may cause off-target effects).

Mechanism of Action#

ACE-031 promotes muscle growth through multiple interconnected mechanisms.

Muscle Hypertrophy#

By removing the myostatin inhibitory signal, ACE-031 shifts the balance between muscle protein synthesis and degradation toward net anabolism. This results in increased muscle fiber size (hypertrophy), enhanced satellite cell activation and differentiation, increased expression of myogenic transcription factors (MyoD, myogenin), and reduced expression of the ubiquitin-proteasome pathway components that mediate muscle protein breakdown.

Anti-Adipogenic Effects#

In addition to promoting muscle growth, myostatin pathway inhibition has been shown to reduce adipose tissue accumulation. This dual effect on body composition (increasing lean mass while decreasing fat mass) was observed in clinical studies with ACE-031 and represents an attractive therapeutic profile for metabolic diseases.

Bone Effects#

The ActRIIB receptor also mediates signaling relevant to bone metabolism. ACE-031 has been shown to increase bone mineral density in preclinical models, potentially through inhibition of activin signaling in bone cells. This effect could be beneficial for patients with DMD, who experience progressive bone loss.

Clinical Development History#

Phase 1 -- Healthy Volunteers#

A Phase 1 randomized, double-blind, placebo-controlled study (published 2013, PMID: 23169607) evaluated single ascending doses of ACE-031 in healthy postmenopausal women. The study demonstrated that ACE-031 was generally well tolerated at doses up to 3 mg/kg, that significant dose-dependent increases in lean body mass were observed (up to 1.0 kg mean increase over placebo at 3 mg/kg), that fat mass decreased in the highest dose group, and that bone formation biomarkers increased, suggesting anabolic bone effects.

These results provided the first human evidence that myostatin pathway inhibition could produce meaningful changes in body composition with a single dose.

Phase 2 -- Duchenne Muscular Dystrophy#

A Phase 2 randomized, placebo-controlled trial (published 2017, PMID: 27462804) evaluated ACE-031 in boys with DMD aged 4 and older. The study design included subcutaneous injections every 2 weeks at doses up to 2.5 mg/kg for 12 weeks.

The trial was terminated early by the Data Safety Monitoring Board due to safety concerns. Specific safety signals included minor epistaxis (nosebleeds) occurring in several treated subjects, telangiectasias (dilated blood vessels) appearing on the skin, and gingival bleeding. These vascular effects were attributed to the inhibition of BMP9 and BMP10 signaling through the ActRIIB receptor. BMP9 and BMP10 are critical regulators of vascular development and endothelial cell function, and their inhibition by ACE-031 led to vascular abnormalities.

Despite the safety concerns, the study provided preliminary evidence of biological activity, including increases in lean body mass and bone mineral density in treated boys.

Development Discontinuation#

Following the DMD trial safety findings, Acceleron Pharma discontinued the clinical development of ACE-031 in 2013. The company redirected its efforts toward more selective myostatin pathway inhibitors that would avoid the off-target vascular effects caused by BMP9/10 inhibition.

Legacy and Impact#

Although ACE-031 itself did not progress to approval, its development program made several important contributions to the field. It provided the first clinical proof of concept that myostatin pathway inhibition can increase lean body mass in humans. It identified the vascular toxicity associated with broad ActRIIB inhibition, guiding the design of safer next-generation molecules. It informed the development of luspatercept (Reblozyl), a modified ActRIIB-Fc fusion protein that was designed to avoid BMP9/10 inhibition and was subsequently approved for anemia in myelodysplastic syndromes and beta-thalassemia. It also advanced the understanding of TGF-beta superfamily biology in muscle and vascular tissue.

Current Status#

ACE-031 is no longer in clinical development. It remains available only as a research tool from specialty suppliers. The myostatin inhibition field has moved toward more selective approaches including anti-myostatin antibodies (domagruzumab), myostatin propeptide-based inhibitors, and modified ActRIIB constructs with reduced BMP9/10 binding. The lesson from ACE-031, that broad ligand inhibition through the ActRIIB decoy approach carries unacceptable vascular risks, has been fundamental in shaping the development strategy for the entire myostatin inhibitor drug class.

Key Research Findings#

Safety, tolerability, pharmacokinetics, and pharmacodynamics of ACE-031 in healthy volunteers, published in Muscle and Nerve (Attie KM et al., 2013; PMID: 23169607):

Phase 1 randomized, double-blind, placebo-controlled study of single ascending doses of ACE-031 in healthy postmenopausal women demonstrating dose-dependent lean body mass increases.

• ACE-031 was generally well tolerated at single doses up to 3 mg/kg
• Significant dose-dependent increases in lean body mass (up to 1.0 kg at 3 mg/kg over 29 days)
• Fat mass decreased at the highest dose level

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial, published in Muscle and Nerve (Campbell C et al., 2017; PMID: 27462804):

Phase 2 randomized, placebo-controlled trial of ACE-031 in boys with DMD, terminated early due to vascular safety signals (epistaxis, telangiectasias).

• Study terminated early by DSMB due to vascular adverse events (epistaxis, telangiectasias)
• Preliminary evidence of lean body mass and bone mineral density increases in treated boys
• Vascular effects attributed to BMP9/10 inhibition through the ActRIIB receptor

Related Reading#

• ACE-031 research studies and evidence
• ACE-031 dosing protocols
• ACE-031 side effects profile
• Bimagrumab research guide
• Follistatin research guide